Last reviewed · How we verify

Abacavir sulfate, Lamivudine and Zidovudine

National Institute of Allergy and Infectious Diseases (NIAID) · FDA-approved active Small molecule

Abacavir sulfate, Lamivudine and Zidovudine is a Nucleoside reverse transcriptase inhibitor (NRTI) combination Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently FDA-approved for HIV-1 infection.

This combination of three nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.

This combination of three nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection.

At a glance

Generic nameAbacavir sulfate, Lamivudine and Zidovudine
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Drug classNucleoside reverse transcriptase inhibitor (NRTI) combination
TargetHIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

Abacavir, lamivudine, and zidovudine are all NRTIs that inhibit HIV reverse transcriptase by competing with natural nucleosides and causing chain termination during viral DNA synthesis. When used together, they provide synergistic suppression of HIV replication and reduce the likelihood of resistance development. This triple-NRTI regimen was historically used as a backbone for antiretroviral therapy before the advent of more potent combination regimens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Abacavir sulfate, Lamivudine and Zidovudine

What is Abacavir sulfate, Lamivudine and Zidovudine?

Abacavir sulfate, Lamivudine and Zidovudine is a Nucleoside reverse transcriptase inhibitor (NRTI) combination drug developed by National Institute of Allergy and Infectious Diseases (NIAID), indicated for HIV-1 infection.

How does Abacavir sulfate, Lamivudine and Zidovudine work?

This combination of three nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.

What is Abacavir sulfate, Lamivudine and Zidovudine used for?

Abacavir sulfate, Lamivudine and Zidovudine is indicated for HIV-1 infection.

Who makes Abacavir sulfate, Lamivudine and Zidovudine?

Abacavir sulfate, Lamivudine and Zidovudine is developed and marketed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).

What drug class is Abacavir sulfate, Lamivudine and Zidovudine in?

Abacavir sulfate, Lamivudine and Zidovudine belongs to the Nucleoside reverse transcriptase inhibitor (NRTI) combination class. See all Nucleoside reverse transcriptase inhibitor (NRTI) combination drugs at /class/nucleoside-reverse-transcriptase-inhibitor-nrti-combination.

What development phase is Abacavir sulfate, Lamivudine and Zidovudine in?

Abacavir sulfate, Lamivudine and Zidovudine is FDA-approved (marketed).

What are the side effects of Abacavir sulfate, Lamivudine and Zidovudine?

Common side effects of Abacavir sulfate, Lamivudine and Zidovudine include Hypersensitivity reaction (abacavir), Nausea, Headache, Diarrhea, Fatigue, Lactic acidosis (rare).

What does Abacavir sulfate, Lamivudine and Zidovudine target?

Abacavir sulfate, Lamivudine and Zidovudine targets HIV reverse transcriptase and is a Nucleoside reverse transcriptase inhibitor (NRTI) combination.

Related